Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 3/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.34 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5604492 | 0.77 | FFAR4 (0.41) | GPR84FFAR1PTGER4PTGER3PTGER2 | |
| SCHEMBL11777636 | 0.73 | TP53 (0.36) | GPR84FFAR1CA2PTGER2KDM4E | |
| SCHEMBL11779919 | 0.73 | TP53 (0.36) | GPR84FFAR1CA2PTGER2KDM4E | |
| SCHEMBL11796563 | 0.73 | TP53 (0.36) | GPR84FFAR1CA2PTGER2KDM4E | |
| SCHEMBL11776997 | 0.73 | TP53 (0.36) | GPR84FFAR1CA2PTGER2KDM4E | |
| SCHEMBL5489484 | 0.71 | GPR84 (0.42) | GPR84FFAR1CA2FFAR4KDM4E | |
| SCHEMBL28171081 | 0.71 | GPR84 (0.42) | GPR84FFAR1CA2FFAR4KDM4E | |
| SCHEMBL5482895 | 0.71 | GPR84 (0.42) | GPR84FFAR1CA2FFAR4KDM4E | |
| SCHEMBL7296440 | 0.71 | PDCD4 (0.41) | GPR84FFAR1CA2 | |
| SCHEMBL4184971 | 0.71 | ESR1 (0.38) | TOP1GPR84FFAR1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312336-A1 | Preventive and/or Therapeutic Agent for Diabetic Vascular Disorder and Respiratory Disorder | UNIVERSITE DE STRASBOURG (FR) | 2008-12-18 | — | — | US | claimed |
| US-7166642-B1 | Use of cyclohexenone long-chain alcohol for treating neurodegenerative diseases | MEIJI DAIRIES CORPORATION (JP) | 2007-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312336-A1 | Preventive and/or Therapeutic Agent for Diabetic Vascular Disorder and Respiratory Disorder | CPT1B, CHRM1, ADRA1D | TOP1 2847/4885GPR84 423/4885FFAR1 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.